West Pharmaceutical Services Inc Performed Better

West Pharmaceutical Services Inc. shares inched 0.89% higher to $368.99 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.20% to 4,343.54 and Dow Jones Industrial Average DJIA falling 0.60% to 34,577.37.

West Pharmaceutical Services Inc. hit a new 52-week high, surpassing its previous peak of $365.98, which the company achieved on July 2nd. The stock outperformed some of its competitors Tuesday, as Johnson & Johnson JNJ fell 0.60% to $167.97, Medtronic PLC MDT rose 0.11% to $126.97, and Stryker Corp. SYK fell 0.21% to $264.86.

West Pharmaceutical Services Inc trading volume (592,182) eclipsed its 50-day average volume of 389,037. This was the stock’s third consecutive day of gains. West Pharmaceutical Services had US$254.6m of debt, in March 2021, which is about the same as the year before. You can click the chart for greater detail. However, it does have US$483.7m in cash offsetting this, leading to net cash of US$229.1m.

West Pharmaceutical Services had liabilities of US$482.8m due within 12 months and liabilities of US$427.9m due beyond that. On the other hand, it had cash of US $483.7m and US$465.7m worth of receivables due within a year. So it can boast US$38.7m more liquid assets than total liabilities. West Pharmaceutical Services recorded free cash flow worth 68% of its EBIT, which is around normal, given free cash flow excludes interest and tax.